Literature DB >> 23020726

Advancing personalized cancer medicine in lung cancer.

Laura E MacConaill1.   

Abstract

Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges must be addressed before the goal of personalized cancer therapy can become a reality for lung cancer patients.

Entities:  

Mesh:

Year:  2012        PMID: 23020726     DOI: 10.5858/arpa.2012-0244-SA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  2 in total

1.  Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells.

Authors:  I Ischenko; J Liu; O Petrenko; M J Hayman
Journal:  Cell Death Differ       Date:  2014-03-28       Impact factor: 15.828

2.  [Lung cancer. Molecular pathology and personalized therapy].

Authors:  A Schultheis; J Wolf; R Büttner
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.